COMP <GO>
CGEN vs JNJ // ENTERPRISE SCALE & MARKET CAP
Compugen Ltd. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CGEN 8
— JNJ 3
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $1.98 (-2.94%) • MKT CAP: $193.0M
market-cap
$193.0M
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGEN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CGEN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.30% | 67.90% | +19.40 | CGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 25.50% | +59.50 | CGEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.2x | 18.5x | -15.30 | CGEN | /valuation <GO> |
| Free Cash Flow Yield | 16.24% | 2.97% | +13.27 | CGEN | /fcf-yield <GO> |
| Operating Margin | 43.10% | 34.70% | +8.40 | CGEN | /operating-margins <GO> |
| Net Profit Margin | 48.60% | 28.50% | +20.10 | CGEN | /net-margins <GO> |
| Revenue Growth (YoY) | 161.10% | 6.00% | +155.10 | CGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 62.1 | -20.96 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.6x | 23.0x | -18.40 | CGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $193.0M | $662.49B | -$662.30B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CGEN REV | JNJ REV | CGEN GROSS % | JNJ GROSS % | CGEN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $72.8M | $94.19B | 87.3% | 67.9% | $31.3M | $19.70B |
| FY 2024 | $27.9M | $88.82B | 71.5% | 69.1% | $49.5M | $19.84B |
| FY 2023 | $33.5M | $85.16B | — | — | -$35.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGEN // BETA —
JNJ // BETA 1.08